- JP-listed companies
- Renascience Inc.
- Income statement
Renascience Inc. (4889) Income statement
Market cap
¥18.4B
P/E ratio
-53.3x
Rena Science develops pharmaceuticals, medical devices, and AI-powered software to address critical health challenges including cancer, diabetes, and age-related diseases.
| 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| Revenue | 70 | 9 | - | 72 | 210 | 139 | 101 | 194 | 133 |
| Revenue growth (%) | - | - | - | ||||||
| Gross profit | - | - | - | 52 | 180 | 81 | 100 | 166 | 129 |
| Gross margin (%) | - | - | - | ||||||
| Operating margin (%) | - | - | - | ||||||
| Operating income | - | - | - | -183 | -86 | -211 | -334 | -252 | -179 |
| Income before tax | -2 | -31 | -151 | -184 | -91 | -242 | -334 | -252 | -179 |
| Pretax margin (%) | -2.8 | -331.3 | - | -255.2 | -43.2 | -173.5 | -332 | -129.7 | -134.9 |
| Provision for income taxes | - | - | - | 0 | 0 | 1 | 2 | 2 | 30 |
| Effective tax rate (%) | - | - | - | ||||||
| Net income | -2 | -70 | -151 | -184 | -100 | -254 | -336 | -258 | 113 |
| Net income margin (%) | - | ||||||||
| Earnings per share | -17,508.66 | -594,040.37 | -4,682.64 | -18.75 | -10.19 | -22.33 | -26.42 | -20.32 | 8.92 |
| Dividend per share | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | ||||||
| EBITDA margin (%) | - | - | - |